These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 21166717

  • 21. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N, Evangelista ML, Amadori S, Stasi R.
    Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
    [Abstract] [Full Text] [Related]

  • 22. Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases.
    Li HQ, Zhang L, Zhao H, Ji LX, Yang RC.
    Chin Med J (Engl); 2005 Jan 05; 118(1):34-7. PubMed ID: 15642223
    [Abstract] [Full Text] [Related]

  • 23. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P, Stipa E, La Presa M, Bianchi M, Di Giulio C, Stasi R, Amadori S.
    Recenti Prog Med; 2002 Jan 05; 93(7-8):421-7. PubMed ID: 12138687
    [Abstract] [Full Text] [Related]

  • 24. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura.
    Dan K, Gomi S, Kuramoto A, Maekawa T, Nomura T.
    Int J Hematol; 1992 Jun 05; 55(3):287-92. PubMed ID: 1498319
    [Abstract] [Full Text] [Related]

  • 25. [Outline of treatment--strategy of initial therapy].
    Ohtake H, Miyazaki K, Higashihara M.
    Nihon Rinsho; 2003 Apr 05; 61(4):587-92. PubMed ID: 12718080
    [Abstract] [Full Text] [Related]

  • 26. Sequence of treatments for adults with primary immune thrombocytopenia.
    George JN.
    Am J Hematol; 2012 May 05; 87 Suppl 1():S12-5. PubMed ID: 22389032
    [Abstract] [Full Text] [Related]

  • 27. Current options for the treatment of idiopathic thrombocytopenic purpura.
    Arnold DM, Kelton JG.
    Semin Hematol; 2007 Oct 05; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
    [Abstract] [Full Text] [Related]

  • 28. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb 05; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 29. Results and prognostic factors of splenectomy in idiopathic thrombocytopenic purpura.
    Winde G, Schmid KW, Lügering N, Fischer R, Brandt B, Berns T, Bünte H.
    J Am Coll Surg; 1996 Dec 05; 183(6):565-74. PubMed ID: 8957458
    [Abstract] [Full Text] [Related]

  • 30. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar 05; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
    Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M, Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto.
    Haematologica; 2005 Jan 05; 90(1):72-7. PubMed ID: 15642672
    [Abstract] [Full Text] [Related]

  • 32. Current therapies in primary immune thrombocytopenia.
    Pels SG.
    Semin Thromb Hemost; 2011 Sep 05; 37(6):621-30. PubMed ID: 22102265
    [Abstract] [Full Text] [Related]

  • 33. Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China.
    Zhou H, Fu R, Wang H, Zhou F, Li H, Zhou Z, Zhang L, Yang R.
    Ann Hematol; 2013 Jan 05; 92(1):79-87. PubMed ID: 22956151
    [Abstract] [Full Text] [Related]

  • 34. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F.
    Eur J Haematol Suppl; 2008 Feb 05; (69):19-26. PubMed ID: 18211569
    [Abstract] [Full Text] [Related]

  • 35. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep 05; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 36. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H, Gruhn B, Werner U, Schorner U, Häfer R, Zintl F, Barz D.
    Acta Haematol; 2004 Sep 05; 111(4):221-4. PubMed ID: 15153715
    [Abstract] [Full Text] [Related]

  • 37. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
    Delgado J, Bustos JG, Jimenez-Yuste V, Hernandez-Navarro F.
    Haematologica; 2002 Feb 05; 87(2):215-6. PubMed ID: 11836172
    [Abstract] [Full Text] [Related]

  • 38. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial.
    Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Keshtkar-Jahromi M, Esfahani FS.
    Am J Hematol; 2008 May 05; 83(5):376-81. PubMed ID: 18183613
    [Abstract] [Full Text] [Related]

  • 39. The effect of platelet autoantibodies on the course of the disease and clinical response of patients with idiopathic thrombocytopenic purpura.
    Sikorska A, Konopka L, Maślanka K.
    Int J Lab Hematol; 2008 Feb 05; 30(1):58-64. PubMed ID: 18190469
    [Abstract] [Full Text] [Related]

  • 40. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct 05; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.